NG2-proteoglycan-dependent contributions of oligodendrocyte progenitors and myeloid cells to myelin damage and repair

Journal of Neuroinflammation

William B. Stallcup¹  Karolina Kucharova¹ 

[1] Sanford Burnham Prebys Medical Discovery Institute, 10901 North Torrey Pines Road, La Jolla 92037, CA, USA

关键词: Conditional knockout mice;    CSPG4;    NG2;    Axon loss;    Macrophages/microglia;    Oligodendrocyte progenitors;    Remyelination;    Demyelination;   

Others  :  1227066
DOI  :  10.1186/s12974-015-0385-6

 received in 2015-01-27, accepted in 2015-08-20,  发布年份 2015

【 摘 要 】

Background

The NG2 proteoglycan is expressed by several cell types in demyelinated lesions and has important effects on the biology of these cells. Here we determine the cell-type-specific roles of NG2 in the oligodendrocyte progenitor cell (OPC) and myeloid cell contributions to demyelination and remyelination.

Methods

We have used Cre-Lox technology to dissect the cell-type-specific contributions of NG2 to myelin damage and repair. Demyelination is induced by microinjection of 1 % lysolecithin into the spinal cord white matter of control, OPC-specific NG2-null (OPC-NG2ko), and myeloid-specific NG2-null (My-NG2ko) mice. The status of OPCs, myeloid cells, axons, and myelin is assessed by light, immunofluorescence, confocal, and electron microscopy.

Results

In OPC-NG2ko mice 1 week after lysolecithin injection, the OPC mitotic index is reduced by 40 %, resulting in 25 % fewer OPCs at 1 week and a 28 % decrease in mature oligodendrocytes at 6 weeks post-injury. The initial demyelinated lesion size is not affected in OPC-NG2ko mice, but lesion repair is delayed by reduced production of oligodendrocytes. In contrast, both the initial extent of demyelination and the kinetics of lesion repair are decreased in My-NG2ko mice. Surprisingly, the OPC mitotic index at 1 week post-injury is also reduced (by 48 %) in My-NG2ko mice, leading to a 35 % decrease in OPCs at 1 week and a subsequent 34 % reduction in mature oligodendrocytes at 6 weeks post-injury. Clearance of myelin debris is also reduced by 40 % in My-NG2ko mice. Deficits in myelination detected by immunostaining for myelin basic protein are confirmed by toluidine blue staining and by electron microscopy. In addition to reduced myelin repair, fewer axons are found in 6-week lesions in both OPC-NG2ko and My-NG2ko mice, emphasizing the importance of myelination for neuron survival.

Conclusions

Reduced generation of OPCs and oligodendrocytes in OPC-NG2ko mice correlates with reduced myelin repair. Diminished demyelination in My-NG2ko mice may stem from a reduction (approximately 70 %) in myeloid cell recruitment to lesions. Reduced macrophage/microglia numbers may then result in decreased myelin repair via diminished clearance of myelin debris and reduced stimulatory effects on OPCs.

【 授权许可】

   
2015 Kucharova and Stallcup.

【 图 表 】

Fig. 1.

Fig. 2.

Fig. 3.

Fig. 4.

Fig. 5.

Fig. 6.

Fig. 7.

【 参考文献 】

• [1]Criste G, Trapp B, Dutta R: Axonal loss in multiple sclerosis: causes and mechanisms. Handb Clin Neurol 2014, 122:101-13.
• [2]Lubetzki C, Stankoff B: Demyelination in multiple sclerosis. Handb Clin Neurol 2014, 122:89-99.
• [3]Keirstead HS, Blakemore WF: The role of oligodendrocytes and oligodendrocyte progenitors in CNS remyelination. Adv Exp Med Biol 1999, 468:183-97.
• [4]Patel JR, McCandless EE, Dorsey D, Klein RS: CXCR4 promotes differentiation of oligodendrocyte progenitors and remyelination. Proc Natl Acad Sci U S A 2010, 107:11062-7.
• [5]Arnett HA, Fancy SP, Alberta JA, Zhao C, Plant SR, Kaing S, et al.: bHLH transcription factor Olig1 is required to repair demyelinated lesions in the CNS. Science 2004, 306:2111-5.
• [6]Gensert JM, Goldman JE: Endogenous progenitors remyelinate demyelinated axons in the adult CNS. Neuron 1997, 19:197-203.
• [7]Dawson MR, Levine JM, Reynolds R: NG2-expressing cells in the central nervous system: are they oligodendroglial progenitors? J Neurosci Res 2000, 61:471-9.
• [8]Horner PJ, Power AE, Kempermann G, Kuhn HG, Palmer TD, Winkler J, et al.: Proliferation and differentiation of progenitor cells throughout the intact adult rat spinal cord. J Neurosci 2000, 20:2218-28.
• [9]Blakemore WF, Franklin RJ: Remyelination in experimental models of toxin-induced demyelination. Curr Top Microbiol Immunol 2008, 318:193-212.
• [10]Bramow S, Frischer JM, Lassmann H, Koch-Henriksen N, Lucchinetti CF, Sorensen PS, et al.: Demyelination versus remyelination in progressive multiple sclerosis. Brain 2010, 133:2983-98.
• [11]Mensah-Brown EP, Shahin A, Al Shamisi M, Lukic ML: Early influx of macrophages determines susceptibility to experimental allergic encephalomyelitis in Dark Agouti (DA) rats. J Neuroimmunol 2011, 232:68-74.
• [12]Trebst C, Konig F, Ransohoff R, Bruck W, Stangel M: CCR5 expression on macrophages/microglia is associated with early remyelination in multiple sclerosis lesions. Mult Scler 2008, 14:728-33.
• [13]Yong VW: Promoting remyelination by reducing an inhibitory microenvironment. Rinsho Shinkeigaku 2010, 50:869.
• [14]Kucharova K, Stallcup WB: The NG2 proteoglycan promotes oligodendrocyte progenitor proliferation and developmental myelination. Neuroscience 2010, 166:185-94.
• [15]Kucharova K, Chang Y, Boor A, Yong VW, Stallcup WB: Reduced inflammation accompanies diminished myelin damage and repair in the NG2 null mouse spinal cord. J Neuroinflammation 2011, 8:158. BioMed Central Full Text
• [16]Moransard M, Dann A, Staszewski O, Fontana A, Prinz M, Suter T: NG2 expressed by macrophages and oligodendrocyte precursor cells is dispensable in experimental autoimmune encephalomyelitis. Brain 2011, 134:1315-30.
• [17]Chang Y, She ZG, Sakimura K, Roberts A, Kucharova K, Rowitch DH, et al.: Ablation of NG2 proteoglycan leads to deficits in brown fat function and to adult onset obesity. PLoS One 2012, 7:e30637.
• [18]You WK, Yotsumoto F, Sakimura K, Adams RH, Stallcup WB: NG2 proteoglycan promotes tumor vascularization via integrin-dependent effects on pericyte function. Angiogenesis 2014, 17:61-76.
• [19]Schuller U, Heine VM, Mao J, Kho AT, Dillon AK, Han YG, et al.: Acquisition of granule neuron precursor identity is a critical determinant of progenitor cell competence to form Shh-induced medulloblastoma. Cancer Cell 2008, 14:123-34.
• [20]Clausen BE, Burkhardt C, Reith W, Renkawitz R, Forster I: Conditional gene targeting in macrophages and granulocytes using LysMcre mice. Transgenic Res 1999, 8:265-77.
• [21]Stockmann C, Doedens A, Weidemann A, Zhang N, Takeda N, Greenberg JI, et al.: Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis. Nature 2008, 456:814-8.
• [22]Ozerdem U, Grako KA, Dahlin-Huppe K, Monosov E, Stallcup WB: NG2 proteoglycan is expressed exclusively by mural cells during vascular morphogenesis. Dev Dyn 2001, 222:218-27.
• [23]de Castro R Jr, Tajrishi R, Claros J, Stallcup WB: Differential responses of spinal axons to transection: influence of the NG2 proteoglycan. Exp Neurol 2005, 192:299-309.
• [24]Larocca JN, Norton WT. Isolation of myelin. Curr Protoc Cell Biol. 2007, Chapter 3:Unit3 25.
• [25]Tigges U, Hyer EG, Scharf J, Stallcup WB: FGF2-dependent neovascularization of subcutaneous Matrigel plugs is initiated by bone marrow-derived pericytes and macrophages. Development 2008, 135:523-32.
• [26]Gibby K, You WK, Kadoya K, Helgadottir H, Young LJ, Ellies LG, et al.: Early vascular deficits are correlated with delayed mammary tumorigenesis in the MMTV-PyMT transgenic mouse following genetic ablation of the NG2 proteoglycan. Breast Cancer Res 2012, 14:R67. BioMed Central Full Text
• [27]Stanley ER. Murine bone marrow-derived macrophages. In: Pollard JW, Walker JM, editors. Basic cell culture protocols. New York City: Humana Press. 1997;75:301-304.
• [28]Yotsumoto F, You WK, Kucharova K, Sakimura K, Stallcup WB: NG2 proteoglycan-dependent recruitment of tumor macrophages promotes pericyte-endothelial cell interactions required for brain tumor vascularization. Oncoimmunology 2015, 4(4):e1001204.
• [29]Grigoriadis N, Grigoriadis S, Polyzoidou E, Milonas I, Karussis D: Neuroinflammation in multiple sclerosis: evidence for autoimmune dysregulation, not simple autoimmune reaction. Clin Neurol Neurosurg 2006, 108:241-4.
• [30]Mikita J, Dubourdieu-Cassagno N, Deloire MS, Vekris A, Biran M, Raffard G, et al.: Altered M1/M2 activation patterns of monocytes in severe relapsing experimental rat model of multiple sclerosis. Amelioration of clinical status by M2 activated monocyte administration. Mult Scler 2011, 17:2-15.
• [31]Petry KG, Brochet B, Dousset V, Vignes JR, Boiziau C: Inflammation induced neurological handicap processes in multiple sclerosis: new insights from preclinical studies. J Neural Transm 2010, 117:907-17.
• [32]Ousman SS, David S: Lysophosphatidylcholine induces rapid recruitment and activation of macrophages in the adult mouse spinal cord. Glia 2000, 30:92-104.
• [33]Franklin RJ: Why does remyelination fail in multiple sclerosis? Nat Rev Neurosci 2002, 3:705-14.
• [34]Dubois-Dalcq M, Ffrench-Constant C, Franklin RJ: Enhancing central nervous system remyelination in multiple sclerosis. Neuron 2005, 48:9-12.
• [35]Miron VE, Franklin RJ: Macrophages and CNS remyelination. J Neurochem 2014, 130:165-71.
• [36]Franklin RJ, Gallo V: The translational biology of remyelination: past, present, and future. Glia 2014, 62:1905-15.
• [37]Goldmann T, Wieghofer P, Muller PF, Wolf Y, Varol D, Yona S, et al.: A new type of microglia gene targeting shows TAK1 to be pivotal in CNS autoimmune inflammation. Nat Neurosci 2013, 16:1618-26.
• [38]Fancy SP, Baranzini SE, Zhao C, Yuk DI, Irvine KA, Kaing S, et al.: Dysregulation of the Wnt pathway inhibits timely myelination and remyelination in the mammalian CNS. Genes Dev 2009, 23:1571-85.
• [39]Fukushi J, Makagiansar IT, Stallcup WB: NG2 proteoglycan promotes endothelial cell motility and angiogenesis via engagement of galectin-3 and alpha3beta1 integrin. Mol Biol Cell 2004, 15:3580-90.
• [40]Chekenya M, Krakstad C, Svendsen A, Netland IA, Staalesen V, Tysnes BB, et al.: The progenitor cell marker NG2/MPG promotes chemoresistance by activation of integrin-dependent PI3K/Akt signaling. Oncogene 2008, 27:5182-94.
• [41]Stallcup WB, You WK, Kucharova K, Cejudo-Martin P, Yotsumoto F. NG2 proteoglycan-dependent contributions of pericytes and macrophages to brain tumor vascularization and progression. Microcirculation. 2015, in press.
• [42]Jin H, Su J, Garmy-Susini B, Kleeman J, Varner J: Integrin alpha4beta1 promotes monocyte trafficking and angiogenesis in tumors. Cancer Res 2006, 66:2146-52.
• [43]Ulyanova T, Priestley GV, Nakamoto B, Jiang Y, Papayannopoulou T: VCAM-1 ablation in nonhematopoietic cells in MxCre+ VCAM-1f/f mice is variable and dictates their phenotype. Exp Hematol 2007, 35:565-71.
• [44]Stark K, Eckart A, Haidari S, Tirniceriu A, Lorenz M, von Bruhl ML, et al.: Capillary and arteriolar pericytes attract innate leukocytes exiting through venules and ‘instruct’ them with pattern-recognition and motility programs. Nat Immunol 2013, 14:41-51.
• [45]Grako KA, Ochiya T, Barritt D, Nishiyama A, Stallcup WB: PDGF (alpha)-receptor is unresponsive to PDGF-AA in aortic smooth muscle cells from the NG2 knockout mouse. J Cell Sci 1999, 112(Pt 6):905-15.
• [46]Makagiansar IT, Williams S, Mustelin T, Stallcup WB: Differential phosphorylation of NG2 proteoglycan by ERK and PKCalpha helps balance cell proliferation and migration. J Cell Biol 2007, 178:155-65.
• [47]Makagiansar IT, Williams S, Dahlin-Huppe K, Fukushi J, Mustelin T, Stallcup WB: Phosphorylation of NG2 proteoglycan by protein kinase C-alpha regulates polarized membrane distribution and cell motility. J Biol Chem 2004, 279:55262-70.
• [48]Cattaruzza S, Ozerdem U, Denzel M, Ranscht B, Bulian P, Cavallaro U, et al.: Multivalent proteoglycan modulation of FGF mitogenic responses in perivascular cells. Angiogenesis 2013, 16:309-27.
• [49]Ozerdem U, Stallcup WB: Pathological angiogenesis is reduced by targeting pericytes via the NG2 proteoglycan. Angiogenesis 2004, 7:269-76.
• [50]Kadoya K, Fukushi J, Matsumoto Y, Yamaguchi Y, Stallcup WB: NG2 proteoglycan expression in mouse skin: altered postnatal skin development in the NG2 null mouse. J Histochem Cytochem 2008, 56:295-303.
• [51]Goretzki L, Burg MA, Grako KA, Stallcup WB: High-affinity binding of basic fibroblast growth factor and platelet-derived growth factor-AA to the core protein of the NG2 proteoglycan. J Biol Chem 1999, 274:16831-7.
• [52]Franklin RJ, Hinks GL: Understanding CNS remyelination: clues from developmental and regeneration biology. J Neurosci Res 1999, 58:207-13.
• [53]Hinks GL, Franklin RJ: Distinctive patterns of PDGF-A, FGF-2, IGF-I, and TGF-beta1 gene expression during remyelination of experimentally-induced spinal cord demyelination. Mol Cell Neurosci 1999, 14:153-68.
• [54]Mason JL, Ye P, Suzuki K, D’Ercole AJ, Matsushima GK: Insulin-like growth factor-1 inhibits mature oligodendrocyte apoptosis during primary demyelination. J Neurosci 2000, 20:5703-8.
• [55]Miron VE, Boyd A, Zhao JW, Yuen TJ, Ruckh JM, Shadrach JL, et al.: Franklin RJ, ffrench-Constant C: M2 microglia and macrophages drive oligodendrocyte differentiation during CNS remyelination. Nat Neurosci 2013, 16:1211-8.
• [56]Shields DC, Schaecher KE, Saido TC, Banik NL: A putative mechanism of demyelination in multiple sclerosis by a proteolytic enzyme, calpain. Proc Natl Acad Sci U S A 1999, 96:11486-91.
• [57]Kotter MR, Zhao C, van Rooijen N, Franklin RJ: Macrophage-depletion induced impairment of experimental CNS remyelination is associated with a reduced oligodendrocyte progenitor cell response and altered growth factor expression. Neurobiol Dis 2005, 18:166-75.
• [58]Zhang Y, Guo TB, Lu H: Promoting remyelination for the treatment of multiple sclerosis: opportunities and challenges. Neurosci Bull 2013, 29:144-54.
• [59]Boda E, Buffo A: Beyond cell replacement: unresolved roles of NG2-expressing progenitors. Front Neurosci 2014, 8:122.
• [60]Irvine KA, Blakemore WF: Remyelination protects axons from demyelination-associated axon degeneration. Brain 2008, 131:1464-77.
• [61]Emerson MR, Gallagher RJ, Marquis JG, LeVine SM: Enhancing the ability of experimental autoimmune encephalomyelitis to serve as a more rigorous model of multiple sclerosis through refinement of the experimental design. Comp Med 2009, 59:112-28.